Sofie Biosciences has raised $2 million from new and existing investors which will be used for the development of new PET imaging agents and systems.

The round includes the first institutional and corporate financing to the firm including investment by the Carpinteria, Calif-based venture capital firm Cycad Group.

The molecular imaging agents are being developed to enable physicians to diagnose disorders in immunology and oncology as well as select the best treatment, said the Culver City, Calif.-based Sofie Biosciences.

Recently, Sofie Biosciences introduced Genisys, a bench-top small animal PET system.